Literature DB >> 18573263

The cost of cerebral ischaemia.

R W V Flynn1, R S M MacWalter, A S F Doney.   

Abstract

Cerebral ischaemia is a major cause of disability and death globally and has a profoundly negative impact on the individuals it affects, those that care for them and society as a whole. The most common and familiar manifestation is stroke, 85% of which are ischaemic and which is the second leading cause of death and most common cause of complex chronic disability worldwide. Stroke survivors often suffer from long-term neurological disabilities significantly reducing their ability to integrate effectively in society with all the financial and social consequences that this implies. These difficulties cascade to their next of kin who often become caregivers and are thus indirectly burdened. A more insidious consequence of cerebral ischaemia is progressive cognitive impairment causing dementia which although less abrupt is also associated with a significant long-term disability. Globally cerebrovascular diseases are responsible for 5.4 million deaths every year (1 in 10 of total). Approximately 3% of total healthcare expenditure is attributable to cerebral ischaemia with cerebrovascular diseases costing EU healthcare systems 21 billion euro in 2003. The cost to the wider economy (including informal care and lost productivity) is even greater with stroke costing the UK 7-8 billion pound in 2005 and the US $62.7 billion in 2007. Cerebrovascular disease cost the EU 34 billion euro in 2003. From 2005 to 2050 the anticipated cost of stroke to the US economy is estimated at $2.2 trillion. Given the global scale of the problem and the enormous associated costs it is clear that there is an urgent need for advances in the prevention of cerebral ischaemia and its consequences. Such developments would result in profound benefits for both individuals and their wider societies and address one of the world's most pre-eminent public health issues.

Entities:  

Mesh:

Year:  2008        PMID: 18573263     DOI: 10.1016/j.neuropharm.2008.05.031

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  71 in total

1.  Polymorphisms of interleukin-10 genes on the risk of ischemic stroke in a meta-analysis.

Authors:  Guo-Ting Yin; Yi-Tong Ma; Ying-Ying Zheng; Yi-Ning Yang; Xiao-Mei Li; Zhen-Yan Fu; Jing-Zhan Zhang; Chuan-Fang Dai; Fen Liu; Bang-Dang Chen; Min-Tao Gai; Xiang Xie
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Towards a dynamical network view of brain ischemia and reperfusion. Part III: therapeutic implications.

Authors:  Donald J Degracia
Journal:  J Exp Stroke Transl Med       Date:  2010

3.  Resveratrol alleviates nerve injury after cerebral ischemia and reperfusion in mice by inhibiting inflammation and apoptosis.

Authors:  Liqun Fang; Hongmei Gao; Weina Zhang; Wenjie Zhang; Yanan Wang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  Valeriana officinalis Extracts Ameliorate Neuronal Damage by Suppressing Lipid Peroxidation in the Gerbil Hippocampus Following Transient Cerebral Ischemia.

Authors:  Dae Young Yoo; Hyo Young Jung; Sung Min Nam; Jong Whi Kim; Jung Hoon Choi; Youn-Gil Kwak; Miyoung Yoo; Sanghee Lee; Yeo Sung Yoon; In Koo Hwang
Journal:  J Med Food       Date:  2015-03-18       Impact factor: 2.786

5.  Building on NeuroNEXT: Next generation clinics to cure chronic neurological disability.

Authors:  Rajiv R Ratan
Journal:  Ann Neurol       Date:  2017-12-08       Impact factor: 10.422

6.  Protein biomarkers for traumatic and ischemic brain injury: from bench to bedside.

Authors:  Zhiqun Zhang; Stefania Mondello; Firas Kobeissy; Richard Rubenstein; Jackson Streeter; Ronald L Hayes; Kevin K W Wang
Journal:  Transl Stroke Res       Date:  2011-12-07       Impact factor: 6.829

Review 7.  Translational MR Neuroimaging of Stroke and Recovery.

Authors:  Emiri T Mandeville; Cenk Ayata; Yi Zheng; Joseph B Mandeville
Journal:  Transl Stroke Res       Date:  2016-08-31       Impact factor: 6.829

8.  Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice.

Authors:  Jean-Christophe Copin; Rafaela F da Silva; Rodrigo A Fraga-Silva; Luciano Capettini; Silvia Quintao; Sébastien Lenglet; Graziano Pelli; Katia Galan; Fabienne Burger; Vincent Braunersreuther; Karl Schaller; Maud Deruaz; Amanda E Proudfoot; Franco Dallegri; Nikolaos Stergiopulos; Robson A S Santos; Yvan Gasche; François Mach; Fabrizio Montecucco
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-19       Impact factor: 6.200

9.  Controlling hypertension immediately post stroke: a cost utility analysis of a pilot randomised controlled trial.

Authors:  Edward Cf Wilson; Gary A Ford; Tom Robinson; Amit Mistri; Carol Jagger; John F Potter
Journal:  Cost Eff Resour Alloc       Date:  2010-03-23

Review 10.  Contribution of transcranial magnetic stimulation to the understanding of functional recovery mechanisms after stroke.

Authors:  Michael A Dimyan; Leonardo G Cohen
Journal:  Neurorehabil Neural Repair       Date:  2009-09-18       Impact factor: 3.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.